A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab
- Status
- RECRUITING
- Phase
- PHASE3
Clinical Trials Related to Risankizumab
Related studies linked through entity extraction aliases.
A Study to Compare the Bioavailability of Intravenously Infused Risankizumab Manufactured by Two Different Processes in Healthy Adults
- Status
- COMPLETED
- Phase
- PHASE1
A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
- Status
- RECRUITING
- Phase
- PHASE3
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis
- Status
- COMPLETED
- Phase
- PHASE4
A Study in Healthy Japanese and Caucasian Subjects to Assess the Pharmacokinetics, Safety and Tolerability of Risankizumab
- Status
- COMPLETED
- Phase
- PHASE1
A Study to Evaluate the Bioavailability of Risankizumab Following Subcutaneous Dosing in Healthy Male Participants
- Status
- COMPLETED
- Phase
- PHASE1
A Study to Evaluate the Bioavailability of Risankizumab in Pre-filled Syringe or Auto-injector in Healthy Adult Participants
- Status
- COMPLETED
- Phase
- PHASE1
High Dose Risankizumab for Psoriasis
- Status
- COMPLETED
- Phase
- PHASE2
Study of Intravenous and Subcutaneous Administration of Risankizumab in Healthy Participants
- Status
- COMPLETED
- Phase
- PHASE1
Study to Evaluate the Effect of Different Warm-Up Times of Risankizumab Autoinjector (AI) on the Injection Pain Experiences in Healthy Volunteers
- Status
- COMPLETED
- Phase
- PHASE1
A Study of Intravenously (IV) Infused or Subcutaneously (SC) Injected Risankizumab in Healthy Adult Participants in China
- Status
- COMPLETED
- Phase
- PHASE1
A Study of Guselkumab and Risankizumab in Healthy Participants and Participants With Psoriatic Arthritis
- Status
- TERMINATED
- Phase
- PHASE1
Study of Subcutaneous Risankizumab Injection Compared to Oral Apremilast Tablets to Assess Change in Disease Activity And Adverse Events in Adult Participants With Moderate Plaque Psoriasis Who Are Candidates for Systemic Therapy
- Status
- COMPLETED
- Phase
- PHASE4
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Study to Evaluate Pregnancy Outcomes in Risankizumab Exposed Pregnancies Relative to Those Non-risankizumab Exposed Pregnancies in Women With FDA Approved Indications
- Status
- RECRUITING
- Phase
- N/A
Study to Assess Adverse Events When Subcutaneous Risankizumab Injection is Given to Adult Participants With Psoriasis in Real World Setting
- Status
- WITHDRAWN
- Phase
- N/A
Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar Involvement
- Status
- COMPLETED
- Phase
- PHASE3
ACTIV-5 / Big Effect Trial (BET-A) for the Treatment of COVID-19
- Status
- COMPLETED
- Phase
- PHASE2
Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Study of Subcutaneous Risankizumab Injection to Assess Change in Palmoplantar Pustulosis Area and Severity Index [PPPASI] in Adult Japanese Participants With Palmoplantar Pustulosis
- Status
- COMPLETED
- Phase
- PHASE3